Involvement of phosphodiesterases in autoimmune diseases

Keren Mizrachi; Revital Aricha; Tali Feferman; Neta Kela-Madar; Ilana Mandel; Tamar Paperna; Ariel Miller; Avraham Ben-Nun; Sonia Berrih-Aknin; Miriam C. Souroujon; Sara Fuchs

doi:10.1016/j.jneuroim.2009.12.012

Involvement of phosphodiesterases in autoimmune diseases

Keren Mizrachi, Revital Aricha, Tali Feferman, Neta Kela-Madar, Ilana Mandel, Tamar Paperna, Ariel Miller, Avraham Ben-Nun, Sonia Berrih-Aknin, Miriam C. Souroujon, Sara Fuchs

Life Sciences discipline

Research output: Contribution to journal › Article › peer-review

Abstract

We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.

Original language	English
Pages (from-to)	43-51
Number of pages	9
Journal	Journal of Neuroimmunology
Volume	220
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2009.12.012
State	Published - 30 Mar 2010

Bibliographical note

Funding Information:
Supported by grants from The Muscular Dystrophy Association of America (MDA) , The Association Francaise Contre les Myopathies (AFM) , The European Commission (MYASTAID , contract LSHM-CT-2006-037833 ) and The Chief Scientist Office, Israel Ministry of Health .

Keywords

Experimental allergic encephalomyelitis (EAE)
Experimental autoimmune myasthenia gravis (EAMG)
Multiple sclerosis (MS)
Myasthenia gravis (MG)
Phosphodiesterases (PDE)

Access to Document

10.1016/j.jneuroim.2009.12.012

Cite this

@article{50ec63739b5e447ea35f8c68ad737337,

title = "Involvement of phosphodiesterases in autoimmune diseases",

abstract = "We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.",

keywords = "Experimental allergic encephalomyelitis (EAE), Experimental autoimmune myasthenia gravis (EAMG), Multiple sclerosis (MS), Myasthenia gravis (MG), Phosphodiesterases (PDE)",

author = "Keren Mizrachi and Revital Aricha and Tali Feferman and Neta Kela-Madar and Ilana Mandel and Tamar Paperna and Ariel Miller and Avraham Ben-Nun and Sonia Berrih-Aknin and Souroujon, {Miriam C.} and Sara Fuchs",

note = "Funding Information: Supported by grants from The Muscular Dystrophy Association of America (MDA) , The Association Francaise Contre les Myopathies (AFM) , The European Commission (MYASTAID , contract LSHM-CT-2006-037833 ) and The Chief Scientist Office, Israel Ministry of Health .",

year = "2010",

month = mar,

day = "30",

doi = "10.1016/j.jneuroim.2009.12.012",

language = "אנגלית",

volume = "220",

pages = "43--51",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Involvement of phosphodiesterases in autoimmune diseases

AU - Mizrachi, Keren

AU - Aricha, Revital

AU - Feferman, Tali

AU - Kela-Madar, Neta

AU - Mandel, Ilana

AU - Paperna, Tamar

AU - Miller, Ariel

AU - Ben-Nun, Avraham

AU - Berrih-Aknin, Sonia

AU - Souroujon, Miriam C.

AU - Fuchs, Sara

N1 - Funding Information: Supported by grants from The Muscular Dystrophy Association of America (MDA) , The Association Francaise Contre les Myopathies (AFM) , The European Commission (MYASTAID , contract LSHM-CT-2006-037833 ) and The Chief Scientist Office, Israel Ministry of Health .

PY - 2010/3/30

Y1 - 2010/3/30

N2 - We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.

AB - We have previously shown that several phosphodiesterase (PDE) subtypes are up-regulated in muscles and lymph node cells (LNC) of rats with experimental autoimmune myasthenia gravis (EAMG). In the present study we investigated PDE expression during the course of EAMG and experimental allergic encephalomyelitis (EAE) and found that the up-regulated expression of selected PDE subtypes in both experimental models is correlated with disease severity. In EAMG, PDE expression is correlated also with muscle damage. A similar up-regulation of PDE was also observed in the respective human diseases, MG and multiple sclerosis (MS). Our findings suggest that change in PDE expression levels is a general phenomenon in autoimmune diseases and may also be used as a marker for disease severity.

KW - Experimental allergic encephalomyelitis (EAE)

KW - Experimental autoimmune myasthenia gravis (EAMG)

KW - Multiple sclerosis (MS)

KW - Myasthenia gravis (MG)

KW - Phosphodiesterases (PDE)

UR - http://www.scopus.com/inward/record.url?scp=77649181513&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2009.12.012

DO - 10.1016/j.jneuroim.2009.12.012

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20100627

AN - SCOPUS:77649181513

SN - 0165-5728

VL - 220

SP - 43

EP - 51

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Involvement of phosphodiesterases in autoimmune diseases

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this